Mikhail Gurevich
Research Subjects
Research Interests
Mikhail Gurevich has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David E. Komatsu
Department of Orthopaedics, Stony Brook University, Stony Brook, NY, USA
4 shared publications Kari Iocolano
Stony Brook University Stony Brook New York USA
2 shared publications- Lina Marie Obeid
Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA
2 shared publications Nicholas U. Schwartz
Health Science Center, L-4, 179, Stony Brook University Medical Center, Stony Brook, NY, 11794-8430, United States
2 shared publicationsYusuf A. Hannun
Health Science Center, L-4, 179, Stony Brook University Medical Center, Stony Brook, NY, 11794-8430, United States
2 shared publicationsAlexander B. Dagum
Division of Plastic and Reconstructive Surgery, Department of Surgery Stony Brook University Hospital Stony Brook New York USA
1 shared publication
Latest Publications
- 3 August 2022
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 33 (13) , 590-596
Leupeptin accelerates recovery after sciatic transection and repair, but not crush injuries in rats
We aimed to explore previously reported discrepancies in success with leupeptin by comparing outcomes of two types of injury: transection and crush. Male rats were randomized into vehicle and leupeptin treatment groups (n = 6/transection group; n = 10/crush group). Leupeptin (12 mg/kg) was administered via intramuscular injection into the gastrocnemius muscle twice a week for the duration of the study. Rats were monitored on a weekly basis for electromyographic function and gait for 8 weeks. A total of 83.3% of the rats that were treated with leupeptin began to recover electromyographic activity 1 week after transection, versus 0% that were treated with leupeptin after crush (P < 0.0001). Rats that were treated with leupeptin also had less functional debilitation, as indicated by a greater sciatic functional index at five of the eight time-points after transection versus one of eight after crush (P ≤ 0.05). Leupeptin aids in the rate of recovery after transection and repair but not crush injuries. These findings suggest there may be differences in pathology and recovery associated with these two types of peripheral nerve injury.
- 3 August 2022
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 33 (13) , 590-596
Leupeptin accelerates recovery after sciatic transection and repair, but not crush injuries in rats
We aimed to explore previously reported discrepancies in success with leupeptin by comparing outcomes of two types of injury: transection and crush. Male rats were randomized into vehicle and leupeptin treatment groups (n = 6/transection group; n = 10/crush group). Leupeptin (12 mg/kg) was administered via intramuscular injection into the gastrocnemius muscle twice a week for the duration of the study. Rats were monitored on a weekly basis for electromyographic function and gait for 8 weeks. A total of 83.3% of the rats that were treated with leupeptin began to recover electromyographic activity 1 week after transection, versus 0% that were treated with leupeptin after crush (P < 0.0001). Rats that were treated with leupeptin also had less functional debilitation, as indicated by a greater sciatic functional index at five of the eight time-points after transection versus one of eight after crush (P ≤ 0.05). Leupeptin aids in the rate of recovery after transection and repair but not crush injuries. These findings suggest there may be differences in pathology and recovery associated with these two types of peripheral nerve injury.
- Open Access
- 3 August 2022
- Published by Wiley in Physiological Reports
- Vol. 10 (15) , e15411
Efficacy of leupeptin in treating ischemia in a rat hind limb model
Prolonged tourniquet use can lead to tissue ischemia and can cause progressive muscle and nerve injuries. Such injuries are accompanied by calpain activation and subsequent Wallerian‐like degeneration. Several known inhibitors, including leupeptin, are known to impede the activity of calpain and associated tissue damage. We hypothesize that employment of leupeptin in a rat model of prolonged hind limb ischemia can mitigate muscle and nerve injuries. Sprague–Dawley rats (n = 10) weighing between 300–400 g were employed in this study. Their left hind limbs were subjected to blood flow occlusion for a period of 2‐h using a neonatal blood pressure cuff. Five rats were given twice weekly intramuscular leupeptin injections, while the other five received saline. After 2 weeks, the animals were euthanized, their sciatic nerves and gastrocnemius muscles were harvested, fixed, stained, and analyzed using NIH Image J software. The administration of leupeptin resulted in larger gastrocnemius muscle fiber cross‐sectional areas for the right (non‐tourniquet applied) hindlimb as compared to that treated with the saline (p = 0.0110). However, no statistically significant differences were found between these two groups for the injured left hindlimb (p = 0.1440). With regards to the sciatic nerve cross‐sectional areas and sciatic functional index, no differences were detected between the leupeptin and control treated groups for both the healthy and injured hindlimbs. This research provides new insights on how to employ leupeptin to inhibit the degenerative effects of calpain and preserve tissues following ischemia resulting from orthopedic or plastic surgery procedures.
- 3 August 2022
- Published by Wiley in Physiological Reports
- Vol. 10 (15) , e15411
Open AccessEfficacy of leupeptin in treating ischemia in a rat hind limb model
Prolonged tourniquet use can lead to tissue ischemia and can cause progressive muscle and nerve injuries. Such injuries are accompanied by calpain activation and subsequent Wallerian‐like degeneration. Several known inhibitors, including leupeptin, are known to impede the activity of calpain and associated tissue damage. We hypothesize that employment of leupeptin in a rat model of prolonged hind limb ischemia can mitigate muscle and nerve injuries. Sprague–Dawley rats (n = 10) weighing between 300–400 g were employed in this study. Their left hind limbs were subjected to blood flow occlusion for a period of 2‐h using a neonatal blood pressure cuff. Five rats were given twice weekly intramuscular leupeptin injections, while the other five received saline. After 2 weeks, the animals were euthanized, their sciatic nerves and gastrocnemius muscles were harvested, fixed, stained, and analyzed using NIH Image J software. The administration of leupeptin resulted in larger gastrocnemius muscle fiber cross‐sectional areas for the right (non‐tourniquet applied) hindlimb as compared to that treated with the saline (p = 0.0110). However, no statistically significant differences were found between these two groups for the injured left hindlimb (p = 0.1440). With regards to the sciatic nerve cross‐sectional areas and sciatic functional index, no differences were detected between the leupeptin and control treated groups for both the healthy and injured hindlimbs. This research provides new insights on how to employ leupeptin to inhibit the degenerative effects of calpain and preserve tissues following ischemia resulting from orthopedic or plastic surgery procedures.
- 1 October 2021
- Published by Medknow in Journal of Arthroscopy and Joint Surgery
- Vol. 8 (4) , 326-332
Effect of 1.5 mm biter-width meniscectomy on cadaveric knee pressure, peak pressure, force, and contact area
- 1 October 2021
- Published by Medknow in Journal of Arthroscopy and Joint Surgery
- Vol. 8 (4) , 326-332
Effect of 1.5 mm biter-width meniscectomy on cadaveric knee pressure, peak pressure, force, and contact area
- 19 February 2019
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 141, 40-48
Quantifying 1-deoxydihydroceramides and 1-deoxyceramides in mouse nervous system tissue
- 19 February 2019
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 141, 40-48
Quantifying 1-deoxydihydroceramides and 1-deoxyceramides in mouse nervous system tissue
- Open Access
- 1 January 2019
- Published by Bloomsbury Academic
- p. 143-162
‘. . . The Film Is Not About That’
- 1 January 2019
- Published by Bloomsbury Academic
- p. 143-162
Open Access‘. . . The Film Is Not About That’
- 1 October 2018
- Published by Frontline Medical Communications, Inc.
- Vol. 47 (10)
The In Vivo Impact of Leukocyte Injections on Normal Rat Achilles Tendons: Potential Detriment to Tendon Morphology, Cellularity, and Vascularity
In this study, we determine the in vivo effects of injecting sub-populations of leukocytes into normal rat Achilles tendons via a controlled laboratory study. Allogenic monocytes, granulocytes, or plasma were injected into 24 healthy rat Achilles tendons. Treated and contralateral un-treated control tendons then assessed for cellularity, histologic morphology, and vascularity
- 1 October 2018
- Published by Frontline Medical Communications, Inc.
- Vol. 47 (10)
The In Vivo Impact of Leukocyte Injections on Normal Rat Achilles Tendons: Potential Detriment to Tendon Morphology, Cellularity, and Vascularity
In this study, we determine the in vivo effects of injecting sub-populations of leukocytes into normal rat Achilles tendons via a controlled laboratory study. Allogenic monocytes, granulocytes, or plasma were injected into 24 healthy rat Achilles tendons. Treated and contralateral un-treated control tendons then assessed for cellularity, histologic morphology, and vascularity
- 1 April 2018
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 43 (4) , 368-373
Emerging Strategies on Adjuvant Therapies for Nerve Recovery
- 1 April 2018
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 43 (4) , 368-373
Emerging Strategies on Adjuvant Therapies for Nerve Recovery
- Open Access
- 3 January 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (3) , 1716-1728
Decreased ceramide underlies mitochondrial dysfunction in Charcot‐Marie‐Tooth 2F
Charcot‐Marie‐Tooth (CMT) disease is the most commonly inherited neurologic disorder, but its molecular mechanisms remain unclear. One variant of CMT, 2F, is characterized by mutations in heat shock protein 27 (Hsp27). As bioactive sphingolipids have been implicated in neurodegenerative diseases, we sought to determine if their dysregulation is involved in CMT. Here, we show that Hsp27 knockout mice demonstrated decreases in ceramide in peripheral nerve tissue and that the disease‐associated Hsp27 S135F mutant demonstrated decreases in mitochondrial ceramide. Given that Hsp27 is a chaperone protein, we examined its role in regulating ceramide synthases (CerSs), an enzyme family responsible for catalyzing generation of the sphingolipid ceramide. We determined that CerSs colocalized with Hsp27, and upon the presence of S135F mutants, CerS1 lost its colocalization with mitochondria suggesting that decreased mitochondrial ceramides result from reduced mitochondrial CerS localization rather than decreased CerS activity. Mitochondria in mutant cells appeared larger with increased interconnectivity. Furthermore, mutant cell lines demonstrated decreased mitochondrial respiratory function and increased autophagic flux. Mitochondrial structural and functional changes were recapitulated by blocking ceramide generation pharmacologically. These results suggest that mutant Hsp27 decreases mitochondrial ceramide levels, producing structural and functional changes in mitochondria leading to neuronal degeneration.—Schwartz, N. U., Linzer, R. W., Truman, J.‐P., Gurevich, M., Hannun, Y. A., Senkal, C. E., Obeid, L. M. Decreased ceramide underlies mitochondrial dysfunction in Charcot‐Marie‐Tooth 2F. FASEB J. 32,1716‐1728 (2018). www.fasebj.org
- 3 January 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (3) , 1716-1728
Open AccessDecreased ceramide underlies mitochondrial dysfunction in Charcot‐Marie‐Tooth 2F
Charcot‐Marie‐Tooth (CMT) disease is the most commonly inherited neurologic disorder, but its molecular mechanisms remain unclear. One variant of CMT, 2F, is characterized by mutations in heat shock protein 27 (Hsp27). As bioactive sphingolipids have been implicated in neurodegenerative diseases, we sought to determine if their dysregulation is involved in CMT. Here, we show that Hsp27 knockout mice demonstrated decreases in ceramide in peripheral nerve tissue and that the disease‐associated Hsp27 S135F mutant demonstrated decreases in mitochondrial ceramide. Given that Hsp27 is a chaperone protein, we examined its role in regulating ceramide synthases (CerSs), an enzyme family responsible for catalyzing generation of the sphingolipid ceramide. We determined that CerSs colocalized with Hsp27, and upon the presence of S135F mutants, CerS1 lost its colocalization with mitochondria suggesting that decreased mitochondrial ceramides result from reduced mitochondrial CerS localization rather than decreased CerS activity. Mitochondria in mutant cells appeared larger with increased interconnectivity. Furthermore, mutant cell lines demonstrated decreased mitochondrial respiratory function and increased autophagic flux. Mitochondrial structural and functional changes were recapitulated by blocking ceramide generation pharmacologically. These results suggest that mutant Hsp27 decreases mitochondrial ceramide levels, producing structural and functional changes in mitochondria leading to neuronal degeneration.—Schwartz, N. U., Linzer, R. W., Truman, J.‐P., Gurevich, M., Hannun, Y. A., Senkal, C. E., Obeid, L. M. Decreased ceramide underlies mitochondrial dysfunction in Charcot‐Marie‐Tooth 2F. FASEB J. 32,1716‐1728 (2018). www.fasebj.org
- 14 September 2012
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 4 (21) , 6722-6725
Heterogeneous nanoclusters assembled by PNA-templated double-stranded DNA
Heterogeneous nanoclusters with trimeric and core–shell architectures containing nanoparticles of different size and composition have been fabricated via site-specific PNA-“invasion” of DNA double helix. This novel strategy facilitates the incorporation of double-stranded DNA into the nanoparticle assembly design.
- 14 September 2012
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 4 (21) , 6722-6725
Heterogeneous nanoclusters assembled by PNA-templated double-stranded DNA
Heterogeneous nanoclusters with trimeric and core–shell architectures containing nanoparticles of different size and composition have been fabricated via site-specific PNA-“invasion” of DNA double helix. This novel strategy facilitates the incorporation of double-stranded DNA into the nanoparticle assembly design.